Roivant Sciences
$35.50Change from previous close: −2.93%Absolute change: −$1.07
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $25.64B
- Enterprise value
- $22.6B
- Forward P/E
- -20.7
- Price/book
- 6.06
- Price/sales
- 3,404.5
- EV/EBITDA
- -16.6
- EV/revenue
- 3,000.3
Profitability and growth
- Gross margin
- 0.0%
- Operating margin
- -25,408.1%
- Net margin
- 0.0%
- ROE
- -8.5%
- ROA
- -16.5%
- Revenue growth (year over year)
- -33.5%
Financial health
- Total cash
- $3.84B
- Total debt
- $107.15M
- Debt/equity
- 0.02
- Current ratio
- 16.7
- Quick ratio
- 13.6
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $48.08
- Median price target
- $46.50
- High price target
- $55.00
- Low price target
- $41.00
- Analysts with a price target
- 12
- Consensus
- Strong buy
- Forward EPS
- -$1.72
- EPS estimate, current year
- -$1.58
Shares and trading
- Beta
- 1.12
- Average volume
- 7.07M
- Shares outstanding
- 722.32M
- Float
- 582.1M
- Institutional ownership
- 78.4%
- Insider ownership
- 21.4%
- Short interest (% of float)
- 6.6%
- Short ratio (days)
- 4.07